We observed the expression and chromatin accessibility of PDCD1 and CXCR4 increased in T‐ALL cells post‐treatment, suggesting PDCD1 and CXCR4 inhibitors may be considered to be used for against refractory T‐ALL. The gene discussed is PDCD1; the disease is acute lymphoblastic leukemia.